TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23388559
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (54 Gy in 1.8 Gy per fraction)
Study: 23388612
Drug: Urine insulin-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine insulin-like growth factor-binding protein 7 (IGFBP7)
Study: 23388612
Drug: Tissue inhibitor
Normalized name: Tissue inhibitor of metalloproteinases 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue inhibitor of metalloproteinases-2 (TIMP-2)
Study: 23390496
Drug: Telbivudine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine monotherapy (600 mg once-daily)
Study: 23390496
Drug: Telbivudine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine plus tenofovir (300 mg once-daily)
Study: 23391200
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of GDF-15 ≥1.8 ng/ml
Study: 23391200
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of NTproBNP (cutoff ≥2,000 pg/ml) or hsTNT (cutoff 14 pg/ml)
Study: 23391248
Drug: Perioperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative systemic polychemotherapy including cetuximab, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) with intraperitoneal oxaliplatin
Study: 23391616
Drug: Topotecan (2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (2.3 mg/m(2)/d) and bevacizumab (15 mg/kg) combination treatment
Study: 23392467
Drug: Atazanavir without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir without tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Study: 23392467
Drug: Atazanavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir with tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Study: 23393105
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (NaHCO3) at doses of 0.3, 0.6, and 1.0 mEq/kg per day
Study: 23393105
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (NaHCO3)
Study: 23394629
Drug: Neoadjuvant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radiochemotherapy with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2
Study: 23396491
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) nicorandil 2 mg
Study: 23396491
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) adenosine infusion (140 μg/kg/min)
Study: 23396491
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) adenosine
Study: 23396557
Drug: Routine iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine iron (n=2184; 60 mg ferrous sulfate plus 400 μg of folic acid daily throughout pregnancy)
Study: 23396557
Drug: Selective iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective iron (n=2142; screening and treatment for anaemia and daily intake of 1 mg of folic acid)
Study: 23398660
Drug: Video capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video capsule endoscopy (Pillcam Eso2; Given Imaging)
Study: 23401442
Drug: R-BAC (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-BAC (rituximab 375 mg/m(2) IV on day 1, bendamustine 70 mg/m(2) IV on days 2 and 3, cytarabine 800 mg/m(2) IV on days 2 to 4) every 28 days for four to six cycles
Study: 23403253
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine at 0.25-1 mg/kg/dose for 14 days
Study: 23403253
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine at 1.5 mg/kg/dose
Study: 23403253
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine at 1 mg/kg/dose
Study: 23403253
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine at 0.25-1 mg/kg/dose
Study: 23403322
Drug: Frequent courses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent courses (three times weekly, n=23)
Study: 23403322
Drug: Infrequent courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrequent courses (≤ 2 times weekly, n=15)
Study: 23410147
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for chronic hepatitis C, specific details not available.
Study: 23411383
Drug: Second-generation EGFR
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation EGFR TKIs (e.g., afatinib, dacomitinib, XL647, AP26113, CO-1686)
Study: 23411383
Drug: First-generation EGFR
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation EGFR TKIs (e.g., erlotinib, gefitinib)
Study: 23411428
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (20,000 IU weekly for 12-13 weeks)
Study: 23414587
Drug: MEK162 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 45 mg for NRAS-mutated melanoma
Study: 23414587
Drug: MEK162 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 45 mg for BRAF-mutated melanoma
Study: 23416850
Drug: Reduced-intensity conditioning
Normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity conditioning regimen (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m(2), thiotepa 10 mg/kg, and 400 cGy total body irradiation with cyclosporine-A/mycophenolate mofetil immunosuppression)
Study: 23417027
Drug: Activin A-neutralizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activin A-neutralizing antibody
Study: 23418272
Drug: Pretreatment CMV
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment CMV DNA of <18,200 (4.3 log(10)) IU/mL
Study: 23418272
Drug: CMV load
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV load suppression <137 IU/mL (<2.1 log(10)) at days 7, 14, and 21
Study: 23425164
Drug: Magnetic device
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic device for sphincter augmentation
Study: 23425514
Drug: Cooled saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled saline intravenous infusions and cooled blankets (historical controls)
Study: 23425608
Drug: Dance intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance intervention twice weekly for eight months in addition to usual school health services
Study: 23426034
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of homocysteine (>9.85 μmol/L)
Study: 23426034
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of homocysteine (≤6.74 μmol/L)
Study: 23426034
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of cysteine (>309 μmol/L)
Study: 23426034
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of cysteine (≤260 μmol/L)
Study: 23426034
Drug: Cysteine association
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine association with rectal tumors
Study: 23426279
Drug: SAR3419 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR3419 + VXL (vincristine/dexamethasone/l-asparaginase)
Study: 23426279
Drug: SAR3419 (protracted
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR3419 (protracted therapy after VXL)
Study: 23426943
Drug: T-Rapa cell
Normalized name: Brassica rapa pollen
DrugBank: Brassica rapa pollen (DB10942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-Rapa cell infusion at day 14 post-HCT
Study: 23426943
Drug: T-Rapa cell
Normalized name: Brassica rapa pollen
DrugBank: Brassica rapa pollen (DB10942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-Rapa cell infusion
Study: 23428875
Drug: PegIFNα-2a 135-180
Normalized name: peginterferon alfa-2a 0.135 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα-2a 135-180 μg/week plus RBV 200-1200 mg/day for 48 weeks
Study: 23429725
Drug: 3'-AmNic-rEPA (4-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3'-AmNic-rEPA (4-400 μg)
Study: 23430175
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin hydrochloride for 3 days after each monthly IVT injection.
Study: 23430598
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT), applied twice a week
Study: 23433846
Drug: AZD8330 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8330 (20 mg BID)
Study: 23433846
Drug: AZD8330 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8330 (various doses)
Study: 23436052
Drug: Conformal radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conformal radiotherapy (RT) and vandetanib (a vascular endothelial growth factor receptor 2 inhibitor)
Study: 23439262
Drug: ABT-450/r 150/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450/r 150/100 mg once daily and ABT-072 400 mg once daily with weight-based ribavirin 1000-1200 mg/day dosed twice daily for 12 weeks
Study: 23439261
Drug: Leptin treatment
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin treatment for 25.8 ± 3.7 months
Study: 23440228
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment via antidepressant medication (n = 126; 22.2%)
Study: 23442518
Drug: Kochujang (KCJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kochujang (KCJ) supplement (32 g/day)
Study: 23442518
Drug: Placebo (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (32 g/day)
Study: 23442588
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (PRV) administered in three doses with an interval of 4 to 10 weeks (28 to 70 days)
Study: 23443507
Drug: UCN-01 65
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCN-01 65 mg/m(2) with perifosine 100 mg a day
Study: 23443507
Drug: Perifosine 150
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine 150 mg every 6 h on day 1 followed by 100 mg once a day continuously in 28-day cycles
Study: 23443507
Drug: UCN-01 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCN-01 at three dose levels (DL1=40 mg/m(2); DL2=65 mg/m(2); DL3=90 mg/m(2))
Study: 23443507
Drug: UCN-01 and
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: UCN-01 and perifosine combination
Study: 23443801
Drug: Temozolomide 150
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150 mg/m(2) administered daily on a seven-day-on, seven-day-off schedule for each 28-day cycle.
Study: 23445875
Drug: Low hepcidin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Study: 23445875
Drug: High hepcidin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Study: 23446180
Drug: Computer-delivered intervention
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-delivered intervention to improve health literacy and HIV medication adherence
Study: 23447001
Drug: Carfilzomib, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd)
Study: 23451906
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of S100B and NSE levels with clinical parameters
Study: 23454241
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil with steroid withdrawal and reduced cyclosporine A (target level 50-90 ng/ml)
Study: 23454694
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat (iv fat)
Study: 23454694
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat (po fat)
Study: 23454694
Drug: Intravenous endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous endotoxin (LPS)
Study: 23456563
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg plus FOLFOX6
Study: 23456563
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg plus reduced CapeOx (capecitabine 850 mg/m(2))
Study: 23456745
Drug: Ofatumumab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (500 mg, 1000 mg)
Study: 23457473
Drug: DNA prime/adenovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA prime/adenovirus boost malaria vaccine (3 monthly doses of DNA plasmids followed by a single boost with adenovirus vectors)
Study: 23457473
Drug: DNA prime/adenovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA prime/adenovirus boost malaria vaccine
Study: 23458624
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and intravenous omega-3 rich lipid emulsion (n-3FA)
Study: 23459496
Drug: Atazanavir-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir-based therapy (including atazanavir, ritonavir, and emtricitabine-tenofovir)
Study: 23459515
Drug: NKG2D/NKp30-independent bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKG2D/NKp30-independent bispecific antibody construct (CD30xCD16A)
Study: 23465037
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 25 mg once weekly to 50 mg twice weekly
Study: 23466307
Drug: Tremelimumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (15 mg/kg IV every 90 days until tumor progression or severe toxicity)
Study: 23468161
Drug: Positive bacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive bacterial culture after sonication in permanent implants
Study: 23468161
Drug: Positive bacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive bacterial culture after sonication in temporary implants
Study: 23468307
Drug: Subcutaneous omacetaxine
Normalized name: OMACETAXINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous omacetaxine 1.25 mg/m² twice daily days 1-14 every 28 days until hematologic response, then days 1-7 every 28 days as maintenance.
Study: 23468538
Drug: Intravascular cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular cooling after intra-arterial reperfusion therapy (IAT)
Study: 23468941
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy (500 mg/day, up-titrated weekly to a maximum 2,000 mg/day for 16 weeks)
Study: 23471087
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 1,200 mg
Study: 23474348
Drug: Farletuzumab with
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Farletuzumab with chemotherapy (carboplatin and taxane)
Study: 23474348
Drug: Farletuzumab with
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Farletuzumab with chemotherapy
Study: 23475281
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m(2)) and carboplatin (AUC = 6 mg/mL·min) followed by maintenance pemetrexed
Study: 23475406
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release (PR; 50-250 mg b.i.d.)
Study: 23477833
Drug: Cixutumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive soft-tissue sarcoma (group A)
Study: 23477833
Drug: Cixutumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive bone sarcoma (group B)
Study: 23477833
Drug: Cixutumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-negative bone and soft-tissue sarcoma (group C)
Study: 23478952
Drug: Telaprevir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (750 mg every 8 hours for 7 days)
Study: 23480759
Drug: Intermittent-high dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent-high dose oral calcitriol 12 μg/day for 3 days per week for up to 3 months (n=2)
Study: 23480759
Drug: Chemotherapeutic drugs
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic drugs (5-fluorouracil, Mitomycin C, and Leucovorin) for 3 cycles (n=3)
Study: 23480759
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose calcitriol in combination with chemotherapeutic drugs (n=4)
Study: 23483536
Drug: Non-ASA NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ASA NSAIDs and acetaminophen
Study: 23483678
Drug: CP-870,893 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-870,893 (0.1 mg/Kg or 0.2 mg/Kg) combined with carboplatin and paclitaxel
Study: 23483678
Drug: CP-870,893 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-870,893 (0.2 mg/Kg)
Study: 23484911
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load of 700 kilocalories per m² of body surface area at 83% fat after an 8-h fast.
Study: 23487538
Drug: Vandetanib therapy
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib therapy
Study: 23488447
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (BIAsp 30) therapy
Study: 23489023
Drug: Vemurafenib (240-360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (240-360 mg twice a day, escalated to 720 mg twice a day)
Study: 23489534
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: High-dose (100 mg) t-PA
Study: 23489534
Drug: Group IV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV: Half-dose (50 mg) t-PA, slow infusion (6 h) without bolus
Study: 23489534
Drug: Group V:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group V: Low-dose (25 mg) t-PA, slow infusion (6 h) without bolus
Study: 23489912
Drug: Sequential finger-thumb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential finger-thumb opposition test
Study: 23490650
Drug: BMS-690514 (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-690514 (200mg daily)
Study: 23490654
Drug: Sequential arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential arm S treated with 5-fluorouracil and leucovorin (LV5FU2) followed by FOLFOX (LV5FU2+oxaliplatin) and then FOLFIRI (LV5FU2+irinotecan)
Study: 23490654
Drug: Combination arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination arm C that begins directly with FOLFOX followed by FOLFIRI
Study: 23490654
Drug: Sequential arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential arm S
Study: 23490654
Drug: Combination arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination arm C
Study: 23494041
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of omega-3 fatty acids daily (840 mg eicosapentaenoic acid/2520 mg docosahexaenoic acid) for 6 months
Study: 23494984
Drug: Darunavir/ritonavir (600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (600/100 mg twice daily)
Study: 23497046
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy for 1 month
Study: 23497305
Drug: Bevacizumab (Avastin™)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin™) in combination with XELOX or mFOLFOX6
Study: 23497305
Drug: Bevacizumab (Avastin™)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin™) in combination with FOLFIRI
Study: 23497336
Drug: Eltrombopag 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 150 mg daily
Study: 23497336
Drug: AI chemotherapy
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI chemotherapy (without eltrombopag)
Study: 23497349
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion therapy (4 × 10 Gy(RBE))
Study: 23497365
Drug: Weekly docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy; 30 mg/m² docetaxel on day 1 and 8, 60 mg/m² cisplatin on day 1, and 70 mg/m² S-1 on days 1 to 14, repeated every 21 days.
Study: 23497558
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo tacrolimus perfusion at a concentration of 20 ng/ml in 1000 ml Custodiol solution
Study: 23497667
Drug: Drug-related problems
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related problems (DRPs) identified in patients presenting with NSC
Study: 23497667
Drug: Drug-related problems
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related problems (DRPs)